“Not So Different”: How a Value-Based Pathway Led to Increased Biosimilar Use

Originally published in the The Center For Biosimilars Web Site It’s no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in the United States, with few products launched relative to those approved, low uptake of the products that are available, and formulary restrictions that sometimes favor branded biologics over biosimilar options. …

“Not So Different”: How a Value-Based Pathway Led to Increased Biosimilar Use Read More »